Ալուվիա

main_info

  • trade_name:
  • Ալուվիա
  • dosage:
  • 100մգ+25մգ(60) պլաստիկե տարայում
  • pharmaceutical_form:
  • դեղահատեր թաղանթապատ
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Ալուվիա
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

8-4-2019

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

FDA today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received antiretroviral treatment for HIV.

FDA - U.S. Food and Drug Administration

28-3-2019

EU/3/15/1467 (Holostem Terapie Avanzate S.r.l.)

EU/3/15/1467 (Holostem Terapie Avanzate S.r.l.)

EU/3/15/1467 (Active substance: Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL17A1-encoding retroviral vector) - Transfer of orphan designation - Commission Decision (2019)2414 of Thu, 28 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004602

Europe -DG Health and Food Safety

28-3-2019

EU/3/15/1466 (Holostem Terapie Avanzate S.r.l.)

EU/3/15/1466 (Holostem Terapie Avanzate S.r.l.)

EU/3/15/1466 (Active substance: Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL7A1-encoding retroviral vector) - Transfer of orphan designation - Commission Decision (2019)2413 of Thu, 28 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004603

Europe -DG Health and Food Safety

28-3-2019

EU/3/15/1465 (Holostem Terapie Avanzate S.r.l.)

EU/3/15/1465 (Holostem Terapie Avanzate S.r.l.)

EU/3/15/1465 (Active substance: Ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a LAMB3-encoding retroviral vector) - Transfer of orphan designation - Commission Decision (2019)2412 of Thu, 28 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004545

Europe -DG Health and Food Safety

25-2-2019

EU/3/16/1674 (Bellicum Pharma GmbH)

EU/3/16/1674 (Bellicum Pharma GmbH)

EU/3/16/1674 (Active substance: Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19) - Transfer of orphan designation - Commission Decision (2019)1630 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004083

Europe -DG Health and Food Safety

17-1-2019


Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, decision type: , therapeutic area: , PIP number: P/0232/2018

Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, decision type: , therapeutic area: , PIP number: P/0232/2018

Opinion/decision on a Paediatric investigation plan (PIP): Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor, decision type: , therapeutic area: , PIP number: P/0232/2018

Europe - EMA - European Medicines Agency

27-8-2018

Strimvelis (Orchard Therapeutics (Netherlands) B.V.)

Strimvelis (Orchard Therapeutics (Netherlands) B.V.)

Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5703 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3854/T/14

Europe -DG Health and Food Safety

1-8-2018

Strimvelis (GlaxoSmithKline Trading Services Limited)

Strimvelis (GlaxoSmithKline Trading Services Limited)

Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Yearly update - Commission Decision (2018)5217 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety

30-7-2018

Zalmoxis (MolMed S.p.A.)

Zalmoxis (MolMed S.p.A.)

Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Renewal - Commission Decision (2018)5118 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/10

Europe -DG Health and Food Safety